MCRB vs. FGEN, NKTR, ZYME, SVRA, TVTX, HRTX, ALXO, PHAT, OLMA, and ALT
Should you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include FibroGen (FGEN), Nektar Therapeutics (NKTR), Zymeworks (ZYME), Savara (SVRA), Travere Therapeutics (TVTX), Heron Therapeutics (HRTX), ALX Oncology (ALXO), Phathom Pharmaceuticals (PHAT), Olema Pharmaceuticals (OLMA), and Altimmune (ALT). These companies are all part of the "pharmaceutical preparations" industry.
Seres Therapeutics (NASDAQ:MCRB) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership.
Seres Therapeutics received 182 more outperform votes than FibroGen when rated by MarketBeat users. Likewise, 72.41% of users gave Seres Therapeutics an outperform vote while only 62.25% of users gave FibroGen an outperform vote.
Seres Therapeutics has higher earnings, but lower revenue than FibroGen. Seres Therapeutics is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks.
Seres Therapeutics has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.
Seres Therapeutics presently has a consensus price target of $6.67, indicating a potential upside of 985.78%. FibroGen has a consensus price target of $2.00, indicating a potential upside of 81.82%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than FibroGen.
Seres Therapeutics has a net margin of 0.00% compared to FibroGen's net margin of -143.57%.
59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 72.7% of FibroGen shares are owned by institutional investors. 5.1% of Seres Therapeutics shares are owned by company insiders. Comparatively, 2.0% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Seres Therapeutics had 1 more articles in the media than FibroGen. MarketBeat recorded 8 mentions for Seres Therapeutics and 7 mentions for FibroGen. FibroGen's average media sentiment score of 0.60 beat Seres Therapeutics' score of -0.01 indicating that FibroGen is being referred to more favorably in the news media.
Summary
Seres Therapeutics beats FibroGen on 12 of the 17 factors compared between the two stocks.
Get Seres Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Seres Therapeutics Competitors List
Related Companies and Tools
